source
- FDA rejects Capricor's Duchenne cell therapy citing serious data integrity violationsThe Food and Drug Administration issued a second rejection of Capricor Therapeutics' cell therapy, deramiocel, aimed at treating Duchenne muscular dystrophy. The agency said the revised application…
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…